InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,951.20
(
0.53%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.24
(
-0.21%
)
Bitcoin
56,963.80
(
0.45%
)
Post# of 137480
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Aggie9518

Send PM Follow Ignore
Followers 11
Posts 1416
Boards Moderated 0
Alias Born 06/15/2005

Aggie9518

Re: None

Thursday, 01/28/2010 2:52:35 PM

Thursday, January 28, 2010 2:52:35 PM

Post# of 137480
ACHN News...Not sure if it has been posted yet.

Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
Compound Demonstrates Excellent Potency Against HCV and Retains Activity Against Resistant Variants

NEW HAVEN, Conn., Jan. 28, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection. The candidate, ACH-2684, demonstrates excellent potency in the low pico-molar range, as well as good pharmacokinetic and safety profiles in pre-clinical studies


http://finance.yahoo.com/news/Achillion-Announces-pz-798360296.html?x=0&.v=1
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up